Combined Inhibition of EZH2 and ATM Is Synthetic Lethal in BRCA1-Deficient Breast Cancer

To validate the role of EZH2 as a therapeutic target and to identify new synergistic drug combinations, scientists performed a high-throughput drug combination screen in various cell lines derived from BRCA1-deficient and -proficient mouse mammary tumors.